Observation versus neck dissection for positron-emission tomography-negative lymphadenopathy after chemoradiotherapy

Behnood Khodayari, Megan E Daly, Matthew Bobinski, D Gregory Farwell, David K. Shelton, Allen M. Chen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Objectives/Hypothesis To analyze outcomes among patients with residual positron-emission tomography (PET)-negative lymphadenopathy after chemoradiotherapy for head and neck cancer based on whether or not they underwent neck dissection. Study Design Retrospective review. Methods Fifty-five patients with stage III/IV squamous cell carcinoma of the head and neck were identified with residual PET-negative lymphadenopathy based on standardized uptake value of <3. All patients had been treated with chemoradiotherapy to a median dose of 70 Gy (range, 60-4 Gy). Results With a median follow-up of 30 months (range, 6-67 months), the 3-year overall survival (85% vs. 81%, P =.57), progression-free survival (88% vs. 88%, P =.42), and local-regional control (96% vs. 100%, P =.68), did not differ between patients treated by neck dissection or observation. Conclusions Omission of neck dissection appears to be reasonable for patients with residual lymphadenopathy but negative PET after chemoradiotherapy for head and neck cancer. Level of Evidence 4. Laryngoscope, 124:902-906, 2014

Original languageEnglish (US)
Pages (from-to)902-906
Number of pages5
JournalLaryngoscope
Volume124
Issue number4
DOIs
StatePublished - 2014

Keywords

  • cancer
  • Chemoradiotherapy
  • lymphadenopathy
  • observation
  • positron-emission tomography

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Observation versus neck dissection for positron-emission tomography-negative lymphadenopathy after chemoradiotherapy'. Together they form a unique fingerprint.

Cite this